Shares Of Micro Cap Biotech Surging On Acquisition Of Exclusive Worldwide Rights to Phase III TLR5 Agonist

Sponsored:

Wednesday, February 12, 2025

Today was a big day for one small cap biotech company. The company announced that they had acquired worldwide exclusive license rights to a late-stage Toll-like Receptor 5 (TLR5) agonist for the treatment of acute radiation syndrome.

The news sparked strong investor interest, driving the stock of Tivic Health Systems, Inc., (Nasdaq: TIVC) up over 118% in mid-morning trading. This milestone marks a major win for the company, which is being rightfully recognized by the investment community.

As mentioned, Tivic Health Systems, Inc. announced that it had acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). 

In addition, the company had acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline.

“Today, we have aggressively accelerated Tivic’s strategic transformation from a single-product, direct-to-consumer company to a diversified therapeutics company—one with a growing pipeline of clinically validated product candidates,” said Jennifer Ernst, Chief Executive Officer of Tivic.

The lead product candidate in the licensing program is a TLR5 agonist, Entolimod for the treatment of acute radiation syndrome (ARS). Market research firm CoherentMI estimates the global acute radiation syndrome (ARS) market to be valued at USD 5.2 billion in 2024 with a compound annual growth rate of five percent from 2024 to 2031.

Under the agreement, Tivic will initially pay Statera $1,200,000 in equity consideration and $300,000 cash to Statera for the use of Entolimod to treat ARS. Tivic can, at its discretion, subsequently add one or more indications, as well as expand its license to include an Entolimod derivative, Entalasta, by exercising the exclusive options granted in the agreement.

Shares of TIVC went wild after the announcement, surging 118% to $0.5129 on massive volume.  The volume surge is simply out of this world, this stock had volume of 140,000 in yesterday’s trade.  Today, one hour into the trading day, volume stands at 159 million. This is clearly a company maker announcement, and we wouldn’t be surprised by significant further upside as this news circulates out to the investment community.

Sponsored: